Tandem Diabetes Care Files 8-K with Corporate Updates

Ticker: TNDM · Form: 8-K · Filed: 2025-12-30T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, filing, financial-reporting

Related Tickers: TNDM

TL;DR

Tandem Diabetes Care filed an 8-K on 12/30/25 for corporate updates as of 12/26/25.

AI Summary

Tandem Diabetes Care, Inc. filed an 8-K on December 30, 2025, reporting events as of December 26, 2025. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and includes financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing indicates potential changes in Tandem Diabetes Care's corporate structure or governance, which could impact its operational framework and shareholder rights.

Risk Assessment

Risk Level: low — The filing is routine and pertains to corporate governance and financial reporting, not immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific amendments were made to Tandem Diabetes Care's Articles of Incorporation or Bylaws?

The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.

What is the nature of the financial statements and exhibits included in this filing?

The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided header information.

When is Tandem Diabetes Care's fiscal year-end?

Tandem Diabetes Care's fiscal year ends on December 31.

What is the principal executive office address for Tandem Diabetes Care?

The principal executive offices are located at 12400 High Bluff Drive, San Diego, California, 92130.

What is the significance of the 'Date as of Change' being December 30, 2025?

This date likely signifies the effective date of the reported changes or the date the information became official for the filing.

From the Filing

0001438133-25-000237.txt : 20251230 0001438133-25-000237.hdr.sgml : 20251230 20251230162952 ACCESSION NUMBER: 0001438133-25-000237 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20251226 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251230 DATE AS OF CHANGE: 20251230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 251614651 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20251226.htm 8-K tndm-20251226 0001438133 FALSE December 31 0001438133 2025-12-26 2025-12-26 0001438133 2025-01-01 2025-12-31   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the &#8

View on Read The Filing